Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Doxorubicin 27Cyclophosphamide 26Radiotherapy 16Gemcitabine 16Filgrastim 11pembrolizumab 10pazopanib 10Radiation 9Docetaxel 9Cisplatin 9fludarabine 7Trabectedin 7Ipilimumab 7Ifosfamide 7Granulocyte Colony-Stimulating Factor 7Etoposide 7Carboplatin 7Busulfan 7Bevacizumab 7olaratumab 6Temozolomide 6Peripheral Blood Stem Cell Transplantation 6Nivolumab 6Mesna 6Melphalan 6selinexor 5Leucovorin 5Irinotecan 5Celecoxib 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma × Tetrahydrouridine × Clear all
NCT02839694 2018-07-05

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡